Home » USA Broker Ratings » Palatin Technologies – Consensus Indicates Potential 267.8% Upside

Palatin Technologies – Consensus Indicates Potential 267.8% Upside

Palatin Technologies with ticker code (PTN) have now 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 3 and 1.5 with the average target price sitting at 2.17. Now with the previous closing price of 0.59 this indicates there is a potential upside of 267.8%. There is a 50 day moving average of 0.55 and the 200 day MA is 0.53. The company has a market capitalisation of $132m. Find out more information at: http://www.palatin.com

Palatin Technologies, a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies was founded in 1986 and is based in Cranbury, New Jersey.

Join us on our new LinkedIn page

Follow us on LinkedIn